Freenome (NASDAQ:FRNM) Cut to Strong Sell at Wall Street Zen

Freenome (NASDAQ:FRNM – Get Free Report) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday, Wall Street Zen reports.

Other analysts also recently issued reports about the company. Leerink Partners started coverage on Freenome in a research note on Friday, August 14th. They issued an “outperform” rating and a $18.00 target price for the company. TD Cowen initiated coverage on shares of Freenome in a research report on Tuesday, August 18th. They set a “buy” rating and a $17.00 price target on the stock. Jefferies Financial Group began coverage on shares of Freenome in a report on Monday, August 17th. They issued a “buy” rating and a $17.00 price objective for the company. Weiss Ratings began coverage on shares of Freenome in a research report on Monday, August 24th. They set a “sell (d+)” rating for the company. Finally, Guggenheim initiated coverage on shares of Freenome in a research note on Thursday, August 20th. They set a “buy” rating and a $21.00 target price on the stock. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Get Our Latest Research Report on FRNM

Freenome Trading Down 5.7%

Shares of Freenome stock opened at $9.36 on Friday. The firm has a market cap of $1.04 billion, a PE ratio of 9.80 and a beta of 0.60. The business’s 50 day moving average is $13.40. Freenome has a 1-year low of $9.28 and a 1-year high of $17.50.

Freenome (NASDAQ:FRNM – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported $1.10 EPS for the quarter. The company had revenue of $183.49 million during the quarter, compared to analyst estimates of $106.50 million.

About Freenome

(Get Free Report)

Freenome is a biotechnology company developing blood-based tests intended to detect cancer at earlier stages. Its approach combines analysis of biological signals—including DNA and other biomarkers—with computational tools to identify patterns associated with disease. The company’s research has focused on multiomics screening, particularly for colorectal cancer. Freenome has evaluated its blood-based colorectal cancer test in clinical studies; the test is investigational, and its availability and regulatory status may vary.

Further Reading

Analyst Recommendations for Freenome (NASDAQ:FRNM)

Receive News & Ratings for Freenome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freenome and related companies with MarketBeat.com's FREE daily email newsletter.